LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
Year: 2022
Type: conference-abstract
Source: Annals of Oncology
Institutions: University of California, Los Angeles, Kindai University, Hôpital de la Croix-Rousse, Royal Free London NHS Foundation Trust, The Royal Free Hospital, Nanjing University of Chinese Medicine, Nanjing General Hospital of Nanjing Military Command, National Cancer Center Hospital East, Hunan Cancer Hospital, Centre Eugène Marquis, Asan Medical Center, University of Ulsan, Fudan University, Zhongshan Hospital, National Taiwan University Hospital, University Medical Center of the Johannes Gutenberg University Mainz, Kanazawa University, Toranomon Hospital, Merck & Co., Inc., Rahway, NJ, USA (United States), Eisai (United States), Tisch Cancer Institute, Universitat de Barcelona, Icahn School of Medicine at Mount Sinai
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4297986221
